Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double-Blind Placebo-Controlled Trial of Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome (HFS)

NCT00486213 is registered in ClinicalTrials.gov with National Cancer Centre, Singapore as lead sponsor.

NCT NCT00486213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00486213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double-Blind Placebo-Controlled Trial of Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome (HFS)
Lead sponsor
National Cancer Centre, Singapore
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2007
Completion date
August 31, 2014
Enrollment
210 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dermatologic complications, palmar-plantar erythrodysesthesia, unspecified adult solid tumor, protocol specific